Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) EBITDA (2017 - 2025)

Historic EBITDA for Organogenesis Holdings (ORGO) over the last 9 years, with Q3 2025 value amounting to $20.7 million.

  • Organogenesis Holdings' EBITDA rose 23205.7% to $20.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.4 million, marking a year-over-year increase of 3441.39%. This contributed to the annual value of -$1.3 million for FY2024, which is 11024.35% down from last year.
  • As of Q3 2025, Organogenesis Holdings' EBITDA stood at $20.7 million, which was up 23205.7% from -$12.6 million recorded in Q2 2025.
  • Organogenesis Holdings' EBITDA's 5-year high stood at $23.6 million during Q2 2021, with a 5-year trough of -$26.7 million in Q1 2025.
  • For the 5-year period, Organogenesis Holdings' EBITDA averaged around $4.6 million, with its median value being $8.0 million (2023).
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 114738.01% in 2021, then crashed by 302578.12% in 2023.
  • Quarter analysis of 5 years shows Organogenesis Holdings' EBITDA stood at $19.8 million in 2021, then tumbled by 55.86% to $8.7 million in 2022, then crashed by 114.56% to -$1.3 million in 2023, then surged by 905.28% to $10.2 million in 2024, then surged by 102.83% to $20.7 million in 2025.
  • Its EBITDA stands at $20.7 million for Q3 2025, versus -$12.6 million for Q2 2025 and -$26.7 million for Q1 2025.